文献速递白血病

达沙替尼再治疗后第二次停用酪氨酸激酶抑制剂实现无治疗缓解:DAstop2 试验中期结果

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
PubMed 文献 · Leukemia · 2024-01-26

DAstop2 是一项前瞻性研究,纳入首次无治疗缓解失败后经任何酪氨酸激酶抑制剂再治疗≥1年的慢性髓性白血病患者,入组后接受达沙替尼治疗额外两年,持续深度分子学缓解≥1年者可行第二次停药。2017年10月至2021年12月共纳入94例,数据分析时62例尝试了第二次停药,中位随访27个月,6、12、24个月无治疗缓解率分别为61%、56%和46%,未见进展至晚期疾病,87%在重启酪氨酸激酶抑制剂后中位3个月内重新达到MR4。

要点

  • 首次无治疗缓解失败后经达沙替尼再治疗,第二次停药安全可行。
  • 第二次停药后6、12、24个月无治疗缓解率分别为61%、56%和46%。
  • 87%的患者在重启酪氨酸激酶抑制剂后中位3个月内重新达到MR4。

核心结论

  • 达沙替尼治疗后第二次尝试无治疗缓解是安全、可行的,无治疗缓解率似乎与首次停用酪氨酸激酶抑制剂试验报告的范围相当。

研究设计与样本

  • DAstop2(ClinicalTrials.gov ID: NCT03573596)是一项前瞻性研究,纳入首次无治疗缓解尝试失败后经任何酪氨酸激酶抑制剂再治疗≥1年的患者。
  • 入组后患者接受达沙替尼治疗额外两年,持续深度分子学缓解≥1年者符合第二次停用酪氨酸激酶抑制剂的条件。
  • 2017年10月至2021年12月共纳入94例患者,数据分析时62例尝试了第二次停药。

主要发现

  • 从第二次停药起中位随访27个月,6、12和24个月的无治疗缓解率分别为61%、56%和46%。
  • 未见进展至晚期阶段疾病。
  • 87%的患者在重启酪氨酸激酶抑制剂后中位3个月内重新达到MR4。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) has become part of routine care for patients with a sustained deep molecular response (DMR). Approximately 50% experience a molecular relapse upon TKI cessation. Most of them quickly regain DMR upon TKI resumption. Whether these patients can achieve a second treatment-free remission (TFR) remains unclear. DAstop2 (ClinicalTrials.gov ID: NCT03573596) is a prospective study including patients with a failed first TFR attempt re-treated with any TKI for ≥ one year. Upon entering the study, patients received the TKI dasatinib for additional two years. Patients with sustained DMR for ≥1 year qualified for a second TKI stop. Ninety-four patients were included between Oct 2017-Dec 2021. At the time of data analysis, 62 patients had attempted a 2nd stop. After a median follow-up of 27 months from 2nd stop, TFR rates were 61, 56 and 46% at 6, 12 and 24 months respectively. No progression to advanced stage disease was seen and 87% had re-achieved MR4 within a median of 3 months from TKI re-initiation. In summary, we show that a 2nd TFR attempt after dasatinib treatment is safe, feasible and TFR rates seem in the range of those reported in trials of a first TKI stop.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Flygt H, Söderlund S, Richter J, et al. Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial. Leukemia. 2024. PMID: 38278960. doi:10.1038/s41375-024-02145-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。